Study summary · research use only
[Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This report describes the Szeged cardiomyopathy and ion channel diseases registry at the Cardiology Center, University of Szeged, which recruits and follows human patients with primary cardiomyopathies and ion channel diseases. It reports 388 patients with hypertrophic cardiomyopathy as the largest group, with 310 patients with dilated cardiomyopathy and 111 patients with long QT syndrome forming two other sizable groups. Analyzed data on the hypertrophic cardiomyopathy group are reported to show similar figures for disease-related mortality, morbidity, and clinical parameters compared to other reported data. The reference is Orv. Hetil., 2017, 158(3), 101-105.
Abstract
The Szeged cardiomyopathy and ion channel diseases registry aims to establish a representative disease-specific registry based on the recruitment of patients with different cardiomyopathies and ion channel diseases followed at the Cardiology Center, University of Szeged. The registry collects patient data on the main forms of primary cardiomyopathies (hypertrophic, dilated, restrictive, arrhythmogenic right ventricular, left ventricular non-compact, tako-tsubo cardiomyopathy) and ion channel diseases (long QT syndrome, short QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia). Patients with hypertrophic cardiomyopathy (388 patients) make up the largest group of patients in the registry. Patients with dilated cardiomyopathy (310 patients) and patients with the long QT syndrome (111 patients) form two other sizable groups. Analyzed data of the group of patients with hypertrophic cardiomyopathy indicate similar figures with regard to disease related mortality and morbidity and clinical parameters. Orv. Hetil., 2017, 158(3), 101-105.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.